List of Excipients in Branded Drug DIACOMIT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BIOCODEX INC	DIACOMIT	stiripentol	68418-7939	FD&C BLUE NO. 2	2029-07-14
BIOCODEX INC	DIACOMIT	stiripentol	68418-7939	FD&C RED NO. 3	2029-07-14
BIOCODEX INC	DIACOMIT	stiripentol	68418-7939	GELATIN	2029-07-14

Diacomit Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Diacomit is an oral stiripentol product used with clobazam for seizures associated with Dravet syndrome in patients aged 2 years and older. Its commercial opportunity is concentrated in pediatric acceptability, dose flexibility, supply-chain efficiency, and differentiated generic or lifecycle formulations rather than in a new active ingredient. The main development targets are palatability, lower capsule burden, flexible administration, and excipient systems that support global pediatric use.

What is Diacomit and which formulations are commercially relevant?

Diacomit contains stiripentol, a small-molecule anticonvulsant marketed by Biocodex. In the United States, the FDA-approved dosage forms are capsules and powder for oral suspension in 250 mg and 500 mg strengths. The product is administered with food and clobazam, with dosing commonly calculated by body weight and divided into three daily doses.[1]

Product attribute	Commercial relevance
Active ingredient	Stiripentol
Indication	Seizures associated with Dravet syndrome
Patient population	Pediatric and adult patients aged 2 years and older
Key co-medication	Clobazam
Dosage forms	Capsules and powder for oral suspension
Strengths	250 mg and 500 mg
Administration	Three divided doses, with food
Primary formulation challenge	High dose burden and pediatric acceptability
Product developer	Biocodex

The powder formulation has greater lifecycle value because it addresses children who cannot swallow capsules. The capsule product remains relevant for older children and adults, but its commercial competitiveness is constrained by the need for multiple daily doses and relatively high total daily quantities.

What excipients are used in Diacomit formulations?

The approved products use conventional oral solid and powder excipient systems. Product-specific inactive ingredients can vary by dosage form and market, so the regulatory label is the controlling source for any equivalence or reformulation analysis.[1,2]

Typical excipient functions in stiripentol products include:

Excipient function	Formulation purpose	Commercial consideration
Diluent or bulking agent	Provides capsule or sachet mass	Lactose sensitivity and global labeling requirements
Binder	Supports granule or powder cohesion	Affects manufacturability and dissolution
Disintegrant	Promotes breakup after administration	Important for immediate-release performance
Lubricant	Reduces tooling friction	Excess levels can slow wetting or dissolution
Glidant	Improves powder flow	Important for high-dose filling accuracy
Capsule shell	Provides oral solid dosage form	Gelatin and colorant restrictions may apply
Flavoring system	Improves pediatric acceptability	Can create stability and regulatory-control issues
Sweetener or taste modifier	Masks bitterness	Central to oral suspension differentiation
Suspending agent	Maintains dose uniformity in liquid	Affects redispersibility and syringe dosing
Buffer or pH modifier	Controls chemical stability and taste	Must remain compatible with stiripentol and packaging

Stiripentol is administered at a relatively high weight-based dose. That increases the importance of excipient efficiency. A formulation with excessive inactive mass can create larger sachets, higher capsule counts, and poorer adherence.

How should an excipient strategy address pediatric use?

The strongest strategy is to treat excipients as a dose-delivery platform rather than as passive ingredients. The formulation should support three requirements: acceptable taste, accurate dosing across body weights, and simple administration with food.

Taste masking

Stiripentol oral powder requires particular attention to bitterness and mouthfeel. Potential approaches include:

• Polymer coating of drug particles
• Ion-exchange or complexation systems
• Lipid or lipid-polymer microparticles
• Taste-masking granules dispersed in a powder matrix
• Flavored multiparticulates
• pH-controlled suppression of bitter perception
• Sweetener and flavor systems compatible with pediatric safety requirements

Taste masking must not delay release in a way that changes exposure or creates a meaningful food effect. The development target is rapid release after swallowing, not simply reduction of initial taste.

Dose flexibility

A weight-based, three-times-daily regimen creates a need for flexible strengths. Commercially useful approaches include:

• Multiple fixed sachet strengths
• Scored or divisible dosage units
• Premeasured sachets for common pediatric weight bands
• Dispersible tablets
• Granules that can be mixed with soft food
• A concentrated liquid or reconstituted suspension

A formulation that reduces caregiver calculations can have commercial value even if it does not materially reduce the amount of active ingredient.

Administration with food

The product label directs administration with food. This creates an excipient opportunity and a development constraint. Lipid-based excipients, surfactants, and food-compatible matrices could improve dispersion or reduce variability, but they may also alter absorption. Any new formulation would require comparative pharmacokinetic work under fed conditions and, where relevant, evaluation across different meal compositions.[1]

What formulation patents and lifecycle opportunities could protect a Diacomit product?

A reformulated stiripentol product could potentially obtain protection through several claim categories:

Protection category	Potential subject matter
Composition	Specific excipient ratios, coating polymers, flavor systems, or suspending agents
Dosage form	Dispersible tablet, granule, sachet, sprinkle product, or concentrated suspension
Method of use	Administration to a defined pediatric weight range or with a specified food vehicle
Manufacturing	Controlled granulation, particle coating, spray drying, or taste-masking process
Stability	Moisture-control system, packaging configuration, or pH-controlled suspension
Device combination	Oral syringe, dosing cup, sachet system, or unit-dose dispenser
Patient segmentation	Administration protocols for children unable to swallow capsules

The strongest formulation claims generally combine a defined product structure with measurable performance. Claims limited to a broad list of conventional excipients are more vulnerable to obviousness and enablement attacks. Better protection may come from a narrow excipient range linked to a demonstrated result, such as improved taste, reduced dose variability, rapid redispersion, or stability under accelerated conditions.

What generic entry risks exist for Diacomit?

The generic risk profile differs by dosage form.

Capsules

Capsules are the most straightforward target for a conventional abbreviated new drug application. A generic sponsor would typically focus on:

• Same active ingredient and strength
• Immediate-release performance
• Bioequivalence under fed conditions
• Comparable impurity and stability profiles
• Acceptable capsule composition
• Compliance with labeling and dosage requirements

A capsule generic may not need to duplicate every inactive ingredient, but excipient changes must not affect bioequivalence, safety, or product performance.

Powder for oral suspension

The powder product presents higher technical risk. A sponsor must address:

• Dose uniformity after mixing
• Redispersibility
• Sedimentation behavior
• Reconstitution volume
• In-use stability
• Oral syringe compatibility
• Flavor and mouthfeel
• Container-closure moisture protection
• Administration with food or soft food

This can create a larger development barrier than the capsule. The powder product also provides greater opportunity for differentiated lifecycle products because pediatric acceptability and dosing convenience are commercially meaningful.

Liquid or dispersible alternatives

A ready-to-use liquid, dispersible tablet, or multiparticulate product could compete with the powder suspension. These products would likely require more extensive formulation and stability work. They may also trigger new-device, packaging, preservative, or pediatric-excipient issues.

What is the FDA regulatory status of Diacomit?

The FDA approved Diacomit in 2018 for use with clobazam in patients aged 2 years and older with Dravet syndrome.[1] The product has orphan-drug status, which provided a period of market exclusivity separate from patent rights. Orphan exclusivity does not prevent all competing products, but it can restrict approval of the same drug for the same indication during the applicable period.

The FDA-approved products are NDA products, and the Orange Book is the relevant source for listed patents, exclusivity codes, and reference-product information.[3] A generic applicant would need to assess the applicable patent certifications, including Paragraph IV exposure where a listed patent is challenged.

When does Diacomit lose exclusivity?

The commercial exclusivity analysis has three separate components:

1. Orphan-drug exclusivity: Tied to the date and scope of the FDA orphan approval.
2. Patent exclusivity: Determined by listed patents, terminal disclaimers, patent-term adjustment, and any pediatric extension.
3. Regulatory exclusivity: Controlled by the NDA approval history and applicable FDA exclusivity codes.

These protections do not necessarily end on the same date. Orphan exclusivity can expire before a formulation patent, while a patent challenge can create litigation risk before the nominal expiration date. The applicable dates must be assessed from the current Orange Book and the underlying patent records rather than from the product launch date alone.[3]

Which companies are challenging Diacomit?

Public competitive risk is more likely to arise from generic manufacturers pursuing stiripentol capsules or oral powder than from biosimilar developers. Diacomit is a small-molecule drug, so biosimilar pathways do not apply. The relevant route is a generic or other abbreviated application, not a biosimilar application.

Paragraph IV litigation risk depends on whether Diacomit patents are listed and whether an applicant certifies that those patents are invalid, unenforceable, or will not be infringed. A definitive list of challengers should be based on current FDA litigation and application records. The principal strategic distinction is between a capsule challenge, which may be technically simpler, and a powder challenge, which may face more formulation-specific barriers.

How strong is the Diacomit patent estate?

The patent estate is potentially stronger for a differentiated pediatric formulation than for the basic stiripentol molecule. Composition-of-matter protection for an older small molecule is less likely to be the primary barrier. Commercial durability may instead depend on:

• Formulation patents
• Manufacturing-process patents
• Taste-masking claims
• Packaging and stability claims
• Method-of-use claims covering Dravet syndrome treatment
• Device or administration-system claims
• Regulatory exclusivity and market penetration

A formulation patent is more commercially valuable when it protects the only practical pediatric presentation. A patent covering a minor excipient substitution may have limited blocking power if a generic can use a different, pharmaceutically acceptable system.

What commercial opportunities exist for excipient suppliers and formulation developers?

The clearest opportunities are in four areas.

Pediatric taste-masking platforms

Suppliers with validated bitter-drug masking systems could target stiripentol granules, sachets, or dispersible tablets. The value proposition is improved adherence and lower caregiver resistance.

Low-dose-volume liquid systems

A concentrated suspension could reduce administration volume. The formulation would need strong dose uniformity, physical stability, and preservative control. This opportunity is commercially attractive but technically demanding.

Unit-dose packaging

Unit-dose sachets or stick packs could reduce caregiver error and improve portability. Moisture-barrier packaging is important for powder products, particularly where the product is reconstituted or mixed immediately before administration.

Excipients with pediatric regulatory acceptance

An excipient platform with established pediatric exposure data, low allergenic potential, and broad geographic acceptance can shorten regulatory development. Lactose, gelatin, artificial colors, preservatives, and certain sweeteners can create market-specific restrictions or labeling complications.

How does Diacomit compare with competing Dravet syndrome therapies?

Therapy	Active ingredient	Formulation opportunity	Competitive issue
Diacomit	Stiripentol	Taste-masked powder, liquid, granules	Three-times-daily dosing and coadministration with clobazam
Fintepla	Fenfluramine	Oral solution and dosing device	Liquid convenience and specialized monitoring
Epidiolex	Cannabidiol	Ready-to-use oral solution	Established liquid administration and broader cannabinoid positioning
Clobazam products	Clobazam	Tablets, suspension, oral films	Used with Diacomit and competes for regimen convenience
Valproate and other antiseizure drugs	Various	Multiple oral dosage forms	Lower-cost alternatives in broader epilepsy treatment

Diacomit’s competitive weakness is administration complexity. Its strength is its role in a defined Dravet syndrome regimen. A formulation that reduces burden without changing the clinical positioning could defend or expand its commercial value.

Key Takeaways

• Diacomit’s main excipient opportunity is pediatric dose delivery, not basic oral-solid formulation.
• Powder for oral suspension has greater differentiation potential than capsules.
• Taste masking, dose uniformity, food-compatible administration, and low-volume delivery are the highest-value technical targets.
• Generic capsule entry is likely to be less technically complex than generic powder entry.
• Diacomit is a small-molecule product, so biosimilar risk is not applicable.
• Patent value is likely to depend on formulation, manufacturing, method-of-use, packaging, and device claims.
• FDA orphan exclusivity, Orange Book listings, patent terms, and Paragraph IV activity must be analyzed separately.
• Excipient suppliers can compete through pediatric acceptability, unit-dose packaging, and globally acceptable safety profiles.

FAQs About Diacomit Excipients and Commercial Strategy

Can Diacomit be reformulated as a liquid?

Yes, a liquid or concentrated suspension is technically possible, but development would require control of dose uniformity, sedimentation, microbial risk, stability, taste, packaging, and oral-syringe delivery.

What is the most attractive generic formulation for stiripentol?

Capsules are the simplest entry target. Powder for oral suspension may offer greater commercial upside but requires more extensive formulation and equivalence work.

Does Diacomit have biosimilar competition?

No. Stiripentol is a small molecule. Competitive products would follow generic or other abbreviated drug-approval pathways rather than the biosimilar pathway.

Which excipient issue is most important for pediatric Diacomit use?

Palatability is the central issue, followed by dose accuracy and the ability to administer the product with food or soft food.

Can an excipient combination receive patent protection?

Potentially. Protection is stronger when the excipient combination is narrowly defined and linked to demonstrated performance, such as improved taste masking, stability, redispersion, or bioequivalence.

References

1. U.S. Food and Drug Administration. (2018). Diacomit (stiripentol) prescribing information.
2. National Library of Medicine. (n.d.). Diacomit: Stiripentol drug label information. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. European Medicines Agency. (2017). Diacomit: European public assessment report.
5. U.S. Food and Drug Administration. (n.d.). Orphan drug designations and approvals database.